In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1228-1237

  Mani, Nagraj ^a   Gross, Christian H ^a   Parsons, Jonathan D ^a   Hanzelka, Brian ^a   Müh, Ute ^a   Mullin, Steve ^a,b   Liao, Yusheng ^a   Grillot, Anne Laure ^a   Stamos, Dean ^a   Charifson, Paul S ^a   Grossman, Trudy H ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBENZIMIDAZOLE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZIMIDAZOLE DERIVATIVE; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DIMETHYL SULFOXIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; DOXYCYCLINE; GYRASE INHIBITOR; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; NOVOBIOCIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VRT 125853; VRT 752586;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CELL VIABILITY; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MORAXELLA CATARRHALIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; BLOOD PROTEINS; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; UREA;

EID: 33645791657     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1228-1237.2006     Document Type: Article

References (31)

1. Aspa, J., O. Rajas, F. Rodrigucz de Castro, J. Blanquer, R. Zalacain, A. Fenoll, R. de Celes, A. Vargas, F. R. Salvanes, P. P. Espana, J. Rello, and A. Torres. 2004. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin. Infect. Dis. 38:787-798.
2. Barrett, C. T., and J. F. Barrett. 2003. Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr. Opin. Biotech. 14:621-626.
3. Bellon, S., J. D. Parsons, Y. Wei, K. Haykawa, L. L. Swenson, P. S. Charifson, J. A. Lippke, R. Aldape, and C. H. Gross. 2004. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. 48:1856-1864.
4. Centers for Disease Control and Prevention. 2004. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. www.cdc.gov/ncidod/hip /NNIS/2004NNISreport.pdf.
5. Champoux, J. J. 2001. DNA topoisomerases: structure, function and mechanism. Annu. Rev. Biochem. 70:369-413.
6. Deibler, R. W., S. Rahmati, and E. L. Zechiedrich. 2001. Topoisomerase IV, alone, unknots DNA in E. coli. Genes Dev. 15:748-761.
7. Drlica, K. 2001. A strategy for fighting antibiotic resistance. ASM News 67:27-33.
8. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet 3:432-442.
9. Gootz, T. D., and K. E. Brighty. 1998. Chemistry and mechanism of action of the quinolone antibacterials, p. 29-80. In V. T. Andriole (ed.), The quinolones, second edition. Academic Press, Inc., New York, N.Y.
10. Gross, C. H., J. D. Parsons, T. H. Grossman, P. S. Charifson, S. Bellon, J. Jernee, M. Dwyer, S. P. Chambers, W. Markland, M. Botfield, and S. A. Raybuck. 2003. Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance. Antimicrob. Agents Chemother. 47: 1037-1046.
11. Heisig, P. 2001. Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects. Planta Med. 67:3-12.
12. Jacobs, M. R. 2003. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens. Pediatr. Infect. Dis. J. 22:S109-S119.
13. Kaatz, G. W., V. V. Moudgal, S. M. Seo, and J. E. Kristiansen. 2003. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:719-726.
14. Kaatz, G. W., F. McAleese, and S. M. Seo. 2005. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob. Agents Chemother. 49: 1857-1864.
15. Kato, J.-I., Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Susuki. 1990. New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404.
16. Kucers, A., S. M. Crowe, M. L. Grayson, and J. F. Hoy (ed.). 1997. The use of antibiotics, 5th edition, p. 663-666. Butterworth-Heinemann, Linacre House, Jordan Hill, Oxford, United Kingdom.
17. Livermore, D. M. 2004. The need for new antibiotics. Clin. Microbiol. Infect. 10(Suppl. 4):1-9.
18. Manjunatha, U. H., M. Dalal, M. Chatterji, D. R. Radha, S. S. Visweswariah, and V. Nagaraja. 2002. Functional characterization of mycobacterial DNA gyrase: an efficient decatenase. Nucleic Acids Res. 30:2144-2153.
19. Maxwell, A., and D. M. Lawson. 2003. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 3:283-303.
20. Morrison, J. F. 1982. The slow-binding, tight-binding inhibition of enzyme catalyzed reactions. Trends Biochem. Sci. 7:102-105.
21. Munoz, R., M. Bustamante, and A. G. de la Campa. 1995. Ser-127-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J. Bacteriol. 177:4166-4170.
22. Mutnick, A. H., V. Enne, and R. N. Jones. 2003. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37:769-774.
23. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edition, volume 23, number 2. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 6th edition, volume 24, number 2. Approved standard M11-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
25. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes, volume 23, number 18. Approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Pottumarthy, S., T. R. Fritsche, and R. N. Jones. 2005. Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn. Microbiol. Infect. Dis. 51:147-150.
27. Sanchez, L., W. Pan, M. Vinas, and H. Nikaido. 1997. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. 179:6855-6857.
28. Schio, L., F. Chatreaux, V. Loyau, M. Murer, A. Ferreira, P. Mauvais, A. Bonnefoy, and M. Klich. 2001. Fine tuning of physico-chemical parameters to optimise a new series of novobiocin analogues. Bioorg. Med. Chem. Lett. 11:1461-1464.
29. Stieger, M., P. Angehrn, B. Wohlgensinger, and H. Gmunder. 1996. GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin. Antimicrob. Agents Chemother. 40:1060-1062.
30. Waites, K. B., L. B. Duffy, T. Schmid, D. Crabb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD127391. Antimicrob. Agents Chemother. 35:1181-1185.
31. Zechiedrich, E. L., A. B. Khodrusky, S. Bachellier, R. Schneider, D. Chen, D. M. J. Lilley, and N. R. Cozzarelli. 2000. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J. Biol. Chem. 11:8103-8113.